Kelyniam Global, Inc. (OTC:KLYG)

Kelyniam Global (OOTC:KLYG) ($0.014; $4.4M market cap) announced Q3 2024 results:

• Q3 sales of $790K vs $640K in the prior year
• Q3 operating profit of $101K vs a loss of $100k in the prior year
• Nine month sales of $2.49 million vs $1.34 million
• Nine month operating profit of $273,248 vs a loss of $329,993 

"We are proud of our profitable growth in 2024," said Bjella. "Our team has been invigorated by rising sales, the addition of new surgeons and hospital customers, and a stringent focus on expense management. These results support Kelyniam's capability to generate cash and capitalize on our operating model's leverage. While pricing pressures persist, strategic growth and diligent expense management have driven the significant turnaround in our operating profit."

Other events occurring in the third quarter included: 

• Greater market acceptance for the CustomizedBoneÔ (hydroxyapatite) regenerative implant
• Greater trial and usage of the NEOS Cranial Loop fixation
• Attendance at the College of Neurological Surgeons annual meeting

Kelyniam Inc., specializes in the rapid production of custom prosthetics utilizing computer aided design and computer aided manufacturing of advanced medical grade polymers.  The Company develops, manufactures, and distributes custom cranial and maxillo-facial implants for patients.

Kelyniam Global (OOTC:KLYG) ($0.012; $3.6M market cap) announced Q2 2024 results:

• Q2 sales of $743K vs $544K in the prior year

• Q2 operating profit of $49K vs a loss of $162k in the prior year

• Six month sales of $1.7 million vs $1.1 million

• Six month operating profit of $172,093 vs a loss of $229,345 

“The increase in profitability was primarily due to increased sales, efficiency improvements and reducing software, insurance and consulting expenses. Sales for the first half of the year have remained strong as additional surgeons request implants with Kelyniam's patented integrated fixation in the PEEK implant product line. Sales from the hydroxyapatite CustomizedBone™ implant with NEOS Cranial Loop fixation also increased as the products continue to gain market acceptance.” 

Kelyniam Inc., specializes in the rapid production of custom prosthetics utilizing computer aided design and computer aided manufacturing of advanced medical grade polymers.  The Company develops, manufactures, and distributes custom cranial and maxillo-facial implants for patients.

Kelyniam Global (OOTC:KLYG) ($0.04; $1.2M market cap) announced Q1 2024 results:

• Q4 sales of $957,447 vs $596,455 in the prior year

• Operating profit of $123,599 vs a loss of $67,978 in the prior year

“Profitability was strongly enhanced by a year's long effort in reconfiguring the Company's structural costs and a tight focus on this year's operations.  The Company saw those efforts pay off with decreased consulting fees and information technology costs which positively affected the bottom line.” 

 "Sales momentum from Q4 continued into Q1, resulting in record growth, quarterly revenue and profit.  Surgeons and Distributors using Kelyniam custom cranial and craniofacial implants have increased, in addition to the level of case complexity. This is a result of proven outcomes, a laser focus on customer service and operations, and Kelyniam's ability to deliver RUSH cases within 24-48 hours to any hospital in the United States.  Interest in the CustomizedBoneä hydroxyapatite osteo-integrative cranial implant continues to grow, particularly due to the indication for pediatric patients. Looking forward we expect to see continued interest in this unique cranial implant because of the recent approval of the NEOS Cranial Loop fixation vs. traditional suturing, resulting in decreased OR time."

Kelyniam Inc., specializes in the rapid production of custom prosthetics utilizing computer aided design and computer aided manufacturing of advanced medical grade polymers.  The Company develops, manufactures, and distributes custom cranial and maxillo-facial implants for patients.